Differences between the 2013 and 2014 hypertension guidelines. Position of the Central American and Caribbean Society for Hypertension and Cardiovascular Prevention;Divergencias entre guías de 2013 y 2014 de la hipertensión arterial. Posición de la Sociedad Centroamericana y del Caribe de Hipertensión y Prevención Cardiovascular

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 37, Issue 3, 2015, Pages 172-178

  Morales Salinas, Alberto ^a   Wyss, Fernando ^b   Coca, Antonio ^c   Ramírez, Agustín J ^d   Valdez, Osiris ^e   Valerio, Luis F ^f  

^a Hospital Universitario Cardiocentro Ernesto Guevara   (Cuba)

^b CARDIOCLINIK   (Guatemala)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^e Hospital Central Romana   (Dominican Republic)

^f Centro de Diagnóstico Cardiovascular Alajuela   (Costa Rica)

Author keywords

Adrenergic beta antagonists; Hypertension; Risk factors

Indexed keywords

CARDIOVASCULAR DISEASE; DISEASE TREATMENT; GUIDELINE; HYPERTENSION; MEDICINE; RISK FACTOR;

CENTRAL AMERICA;

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CARDIOVASCULAR DISEASES; CARIBBEAN; COMPARATIVE STUDY; HEALTH CARE ORGANIZATION; HUMAN; MOTIVATION; PRACTICE GUIDELINE; PREHYPERTENSION; PRIMARY PREVENTION; RISK FACTOR; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CARIBBEAN REGION; GOALS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREHYPERTENSION; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; SOCIETIES, SCIENTIFIC;

EID: 84929739595     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Narayan V, Ali MK, Koplan JP. Global Noncommunicable Diseases - Where Worlds Meet. N Engl J Med. 2010. doi: 10.1056/nejmp1002024.
2. World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens. 1999;17(2):151-83.
3. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72.
4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology. Eur Heart J. 2013;34(28):2159-219.
5. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.
6. Weber MA, Schiffrin EL, White WB, Lindholm LH, Kenerson JG, Flack JM, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community a Statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens.2013;3:3-15.
7. Zanchetti A. What format for hypertension guidelines: a challenge for authors and users. J Hypertens. 2014;32(1):1-2.
8. Borden WB, Maddox TM, Tang F, Rumsfeld JF, Oetgen WJ, Mullen JB, et al. Impact of the 2014 Expert Panel Recommendations for Management of High Blood Pressure on Contemporary Cardiovascular Practice. J Am Coll Cardiol. 2014;64(21):2196-203.
9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet. 2002;360(9349):1903-13.
10. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291-7.
11. Allen N, Berry JD, Ning H, Horn LV, Dyer A, Lloyd-Jones DM. Impact of Blood Pressure and Blood Pressure Change During Middle Age on the Remaining Lifetime Risk for Cardiovascular Disease: The Cardiovascular Lifetime Risk Pooling Project. Circulation. 2012;125(1):37-44.
12. Ueda H, Miyawaki M, Hiraoka H. High-normal blood pressure is associated with new-onset electrocardiographic left ventricular hypertrophy. J Human Hypertens. 2014. doi:10.1038/jhh.2014.21.
13. Ahmed A, Senior R. High normal blood pressure: to treat or not to treat? J Human Hypertens. 2014. doi:10.1038/jhh.2014.24.
14. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middleaged women and men: The Framingham Heart Study. JAMA. 2002;287(8):1003-10.
15. Ryden L, Grant PJ, Anker SD, Berne Ch, Cosentino F, Danchin N, et al. Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad Cardiovascular. Rev Esp Cardiol. 2014;67(2):136.e1-e56.
16. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J. 2010;31(23):2837-40.
17. Tsika EP, Poulimenos LE, Boudoulas KD, Manolis AJ. The J-Curve in Arterial Hypertension: Fact or Fallacy? Cardiology. 2014;129(2):126-35.
18. Morales Salinas, Coca A. Obesidad, actividad física y riesgo cardiovascular: clasificación ergo-antropométrica, variables farmacológicas, biomarcadores y "paradoja del obeso". Med Clin(Barc).2010;134(11):492-8.
19. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD. Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis Population: The 58th Annual Fall Conference and Scientific Sessions. Hypertension. 2005;45(4):811-7.
20. Wilson PWF, Bozeman SR, Burton TM, Hoaglin DC, Ben-Joseph R, Pashos CL. Prediction of First Events of Coronary Heart Disease and Stroke With Consideration of Adiposity.Circulation.2008;118(2);124-30.
21. Granger CB, Goldberg RJ, Dabbous OH, Pieper KS, Eagle KA, Cannon ChP, et al. for the Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345-53.
22. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031-7.
23. Perk J, De Backer G, Gohlke H, Reiner GZ, Verschuren WMM, Albus C, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33(13);1635-701.
24. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56(3):253-61.
25. Elosua R, Morales-Salinas A. Determinación del riesgo cardiovascular global. Caracterización, modelización y objetivos de la prevención cardiovascular según el contexto socio-geográfico. Rev Esp Cardiol Supl. 2011;11(E):2-12.
26. Morales-Salinas A. Predicción del riesgo cardiovascular: ni blanco, ni negro, pero clave para el manejo racional del asintomático. Rev Cubana Cardiovasc. 2013;19(3-4):128-32.
27. D'Agostino RB, Vasan RS, Pencina MJ, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53.
28. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. The Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet.2014;384(9943):591-8.
29. Redón J, Coca A, Lázaro P, Aguilar MD, Cabañas M, Gil N, et al. Factors associated with therapeutic inertia in hypertension: Validation of a predictive model. J Hypertens. 2010;28(8):1770-7.
30. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50-e103.
31. Vanhoutte PM, Gao Y. β-Blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol. 2013;13(2):265-73.
32. Wiysonge CS, Opie LH. β-Blockers as initialtherapy for hypertension. JAMA. 2013;310(17):1851-2.
33. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
34. McGill JB. Optimal use of β-blockers in high-risk hypertension: a guide to dosing equivalence. Vasc Health Risk Manag. 2010;6(1):363-72.
35. Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vasc Health Risk Manag. 2011;7:777-87.
36. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737-42.
37. Curtis BM, O'keefe JH. Autonomic Tone as a Cardiovascular Risk Factor: The Dangers of Chronic Fight or Flight. Mayo Clin Proc. 2002;77(1):45-54.
38. Opie LH. Mechanisms of cardiac contraction and relaxation. In: Libby P, Bonow RO, Mann DL, Zipes DP, ed. Heart Disease: A Textbook of Cardiovascular Medicine, 8th ed. Philadelphia: Elsevier Saunders: 2008. Pp. 509-39.
39. Morales Salinas A, Coca A, Wyss F. Guidelines for Managing High Blood Pressure JAMA. 2014;312(3):293-4.
40. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. REACH Registry Investigators. b-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-9.
41. Morales Salinas A, Coca A. The β-blockers Crumbling Continues?: A critical analysis of the REACH Registry. The Ochsner Journal. 2013;13(1):167.
42. Morales-Salinas A. Atenolol in uncomplicated hypertension: Time for changes. Lancet Neurol. 2010;9(7):652.
43. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115-27.
44. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension. 2010;56(2):196-202.
45. Beckett NS, Peters R, Fletcher AE, et al. Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98.
46. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target, 140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32(12):1500-8.
47. Bangalore S, Gong Y, Cooper-DeHoff RM, Pepine CJ, Messerli FH. 2014 Eighth Joint National Committee Panel Recommendation for Blood Pressure Targets Revisited. Results From the INVEST Study. J Am Coll Cardiol. 2014;64(8):784-93.
48. Wright JT, Fine LJ, Lackland DT, et al. Evidence Supporting a Systolic Blood Pressure Goal of Less Than 150 mm Hg in Patients Aged 60 Years or Older: The Minority View. Ann Intern Med. 2014;160(7):499-503.